Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 277

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage

Open access
Connolly, Stuart J., Sharma, Mukul, Cohen, Alexander T., Demchuk, Andrew M., Członkowska, Anna, Lindgren, Arne G., Molina, Carlos A., Bereczki, Daniel, Toni, Danilo, Seiffge, David J., Tanne, David, Sandset, Else Charlotte, Tsivgoulis, Georgios, Christensen, Hanne, Beyer-Westendorf, Jan, Coutinho, Jonathan M., Crowther, Mark, Verhamme, Peter, Amarenco, Pierre, Roine, Risto O., Mikulik, Robert, Lemmens, Robin, Veltkamp, Roland, Middeldorp, Saskia, Robinson, Thompson G., Milling, Truman John, Tedim-Cruz, Vitor, Lang, Wilfried, Himmelmann, Anders, Ladenvall, Per, Knutsson, Mikael, Ekholm, Ella, Law, Andrew, Taylor, Amanda, Karyakina, Tetyana, Xu, Lizhen, Tsiplova, Kate, Poli, Sven, Kallmünzer, Bernd, Gumbinger, Christoph, Shoamanesh, Ashkan · 2024 · New England Journal of Medicine

Abstract

BACKGROUND: Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied. METHODS: We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care. The primary end point was hemostatic efficacy, defined by expansion of the hematoma volume by 35% or less at 12 hours after baseline, an increase in the score on the National Institutes of Health Stroke Scale of less than 7 points (scores range from 0 to 42, with higher scores indicating worse neurologic deficit) at 12 hours, and no receipt of rescue therapy between 3 hours and 12 hours. Safety end points were thrombotic events and death. RESULTS: A total of 263 patients were assigned to receive andexanet, and 267 to receive usual care. Efficacy was assessed in an interim analysis that included 452 patients, and safety was analyzed in all 530 enrolled patients. Atrial fibrillation was the most common indication for factor Xa inhibitors. Of the patients receiving usual care, 85.5% received prothrombin complex concentrate. Hemostatic efficacy was achieved in 150 of 224 patients (67.0%) receiving andexanet and in 121 of 228 (53.1%) receiving usual care (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 4.6 to 22.2; P = 0.003). The median reduction from baseline to the 1-to-2-hour nadir in anti-factor Xa activity was 94.5% with andexanet and 26.9% with usual care (P<0.001). Thrombotic events occurred in 27 of 263 patients (10.3%) receiving andexanet and in 15 of 267 (5.6%) receiving usual care (difference, 4.6 percentage points; 95% CI, 0.1 to 9.2; P = 0.048); ischemic stroke occurred in 17 patients (6.5%) and 4 patients (1.5%), respectively. There were no appreciable differences between the groups in the score on the modified Rankin scale or in death within 30 days. CONCLUSIONS: Among patients with intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better control of hematoma expansion than usual care but was associated with thrombotic events, including ischemic stroke. (Funded by Alexion AstraZeneca Rare Disease and others; ANNEXA-I ClinicalTrials.gov number, NCT03661528.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2313040

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 277

Metadata

Authors
Connolly, S. J., Sharma, M., Cohen, A. T., Demchuk, A. M., Członkowska, A., Lindgren, A. G., Molina, C. A., Bereczki, D., Toni, D., Seiffge, D. J., Tanne, D., Sandset, E. C., Tsivgoulis, G., Christensen, H., Beyer-Westendorf, J., Coutinho, J. M., Crowther, M., Verhamme, P., Amarenco, P., Roine, R. O., Mikulik, R., Lemmens, R., Veltkamp, R., Middeldorp, S., Robinson, T. G., Milling, T. J., Tedim-Cruz, V., Lang, W., Himmelmann, A., Ladenvall, P., Knutsson, M., Ekholm, E., Law, A., Taylor, A., Karyakina, T., Xu, L., Tsiplova, K., Poli, S., Kallmünzer, B., Gumbinger, C., & Shoamanesh, A.
Venue
New England Journal of Medicine
Published
2024-05-16
Volume
390
Issue
19
Pages
1745-1755
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4396915834
Cited by
277
References
13
FWCI
63.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage. https://app.cochat.ai/papers/10.1056/nejmoa2313040
The paper
Connolly, S. J., Sharma, M., Cohen, A. T., Demchuk, A. M., Członkowska, A., Lindgren, A. G., Molina, C. A., Bereczki, D., Toni, D., Seiffge, D. J., Tanne, D., Sandset, E. C., Tsivgoulis, G., Christensen, H., Beyer-Westendorf, J., Coutinho, J. M., Crowther, M., Verhamme, P., Amarenco, P., . . . Shoamanesh, A. (2024). Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2313040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.